Company Overview and News

0
JKH hits post war valuation lows as second Balendra era beckons

2018-07-04 lankabusinessonline
July4, 2018 (LBO) – The Colombo Stock Exchange has had a tough 2018, and there is no stock where this is more apparent than John Keells Holdings (JKH). JKH has been referred to as Sri Lanka’s bluest of blue chips.
JKELF JKH CTC NTB JKEHY

0
Another 2018 record low for Sri Lanka stocks

2018-06-19 lankabusinessonline
June 19, 2018 (LBO) – The Colombo Stock Exchange continued its slow bleed lower today hitting record lows for the second consecutive day in 2018.
JKELF JKH CTC JKEHY

12
Virtus hosts panel to share knowledge on how women can overcome career challenges

2018-06-06 lankabusinessonline
As more women enter the workforce the pressures and challenges they face only begin to increase each year. Despite these growing obstacles many women persevered and surmounted even the most difficult barrier and reached the upper echelons of industry. Virtusa recently sat down with some of these trailblazers at a panel discussion on ‘How to Achieve Career Nirvana’ to understand the secrets of their success and to impart some wisdom on many who were just starting out on their journey.
STAN 580001 STAB STAN STAC 2888 SCBFF CTC NTB

12
Virtusa hosts panel discussion on how women can overcome career challenges

2018-06-06 lankabusinessonline
As more women enter the workforce the pressures and challenges they face only begin to increase each year. Despite these growing obstacles many women persevered and surmounted even the most difficult barrier and reached the upper echelons of industry. Virtusa recently sat down with some of these trailblazers at a panel discussion on ‘How to Achieve Career Nirvana’ to understand the secrets of their success and to impart some wisdom on many who were just starting out on their journey.
STAN 580001 STAB STAN STAC 2888 SCBFF CTC NTB

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CSE:CTC / CEYLON TOBACCO COMPANY PLC on message board site Silicon Investor.

DCI Telecommunications - DCTC Today CommTouch (CTCH) : a futur Media Metrix Top 10 ?
Comtouch SPAM Solutions (E-Mail) (NASDAQ:CTCH) DCTC / FTEL / FNET
CTCK CraftClick.com Applied Digital Solutions (formerly actc)
Applied Cellular Technology (ACTC) SCTC - Systems u0026 Computer Technology
Continental Resources CTC M ITELD u0026#034;Wavetechu0027s Merger with DCTCu0026#034;